Metals and Alzheimer’s Disease: How Far Have We Come in the Clinic?
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
It is estimated that by the year 2050 there will be more than 1.5 billion people globally over the age of 65 years. Aging is associated with changes to a number of different cellular processes which are driven by a variety of factors that contribute to the characteristic decline in function that is seen across multiple physiological domains/tissues in the elderly (including the brain). Importantly, aging is also the primary risk factor for the development of neurodegenerative disorders such as Alzheimer’s disease. As such, there is an urgent need to provide a greater understanding of both the pathogenesis and treatment of these devastating neurodegenerative disorders. One of the key cellular processes that becomes dysregulated with age and participates both directly and indirectly in age-related dysfunction, is metal homeostasis and the neurochemistry of metalloproteins, the basic science of which has been extensively reviewed in the past. In this review, we will focus on the human clinical intervention trials that have been conducted over approximately the last four decades that have attempted to establish the efficacy of targeting metal ions in the treatment of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ritchie, C. W., Bush, A. I., Mackinnon, A., Macfarlane, S., Mastwyk, M., MacGregor, L., Kiers, L., Cherny, R., Li, Q.-X., Tammer, A., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1685 · Cited by 988 · cited 2×
“These data, together with a significant impact of the treatment on plasma A levels (which was confined to the less severely affected patients, as shown by stratification of the data based upon their ADAS-cog score at baseline), prompted further clinical development of follow-on compounds by Prana Biotechnology.”
BackgroundSelf-citationIntramuscular desferrioxamine in patients with Alzheimer's disease
MCLACHLAN, D. (1991) · The Lancet · doi:10.1016/0140-6736(91)92978-b · Cited by 764
Lannfelt, L., Blennow, K., Zetterberg, H., Batsman, S., Ames, D., Harrison, J., Masters, C. L., Targum, S., Bush, A. I., Murdoch, R., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70167-4 · Cited by 725
Self-citationTau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export
Lei, P., Ayton, S., Finkelstein, D. I., Spoerri, L., Ciccotosto, G. D., Wright, D. K., Wong, B. X. W., Adlard, P. A., Cherny, R. A., Lam, L. Q., et al. (2012) · Nature Medicine · doi:10.1038/nm.2613 · Cited by 594
Self-citationGood, P. F., Perl, D. P., Bierer, L. M., & Schmeidler, J. (1992) · Annals of Neurology · doi:10.1002/ana.410310310 · Cited by 476
Brain iron and ferritin in Parkinson’s and Alzheimer’s diseases
Jellinger, K., Paulus, W., Grundke-Iqbal, I., Riederer, P., & Youdim, M. B. H. (1990) · Journal of Neural Transmission - Parkinson's Disease and Dementia Section · doi:10.1007/bf02252926 · Cited by 445 · cited 1×
“1 for a comparison of the chemical structures) that readily crosses the blod-brain barrier and which can penetrate cellular membranes to form a neutral and lipophilic complex with iron that readily exits cells, and which can redistribute iron to transferrin [44, 45].”
BackgroundConnor, J. R., Snyder, B. S., Beard, J. L., Fine, R. E., & Mufson, E. J. (1992) · Journal of Neuroscience Research · doi:10.1002/jnr.490310214 · Cited by 374
Metals and Alzheimer's disease
Adlard, P. A., & Bush, A. I. (2006) · Journal of Alzheimer's Disease · doi:10.3233/jad-2006-102-303 · Cited by 324
Self-citationRaven, E. P., Lu, P. H., Tishler, T. A., Heydari, P., & Bartzokis, G. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130209 · Cited by 270
Design of clinically useful iron(III)‐selective chelators
Liu, Z. D., & Hider, R. C. (2002) · Medicinal Research Reviews · doi:10.1002/med.1027 · Cited by 266
Cited by
Risk factors for Alzheimer’s disease
A. Armstrong, R. (2019) · Folia Neuropathologica · doi:10.5114/fn.2019.85929 · Cited by 606
Current understanding of metal ions in the pathogenesis of Alzheimer’s disease
Wang, L., Yin, Y.-L., Liu, X.-Z., Shen, P., Zheng, Y.-G., Lan, X.-R., Lu, C.-B., & Wang, J.-Z. (2020) · Translational Neurodegeneration · doi:10.1186/s40035-020-00189-z · Cited by 454
“As both increase and decrease and as well as mislocalization of the metal ions have been observed in AD, several clinical trials by supplementing or chelating or modulating the metal ions have been carried out in AD patients [19].”
BackgroundCopper and Zinc Dysregulation in Alzheimer’s Disease
Sensi, S. L., Granzotto, A., Siotto, M., & Squitti, R. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.10.001 · Cited by 285
Chen, L., Zhao, Y., Liu, F., Chen, H., Tan, T., Yao, P., & Tang, Y. (2022) · BMC Medicine · doi:10.1186/s12916-022-02403-3 · Cited by 211
Chen, Y.-G., He, X.-L.-S., Huang, J.-H., Luo, R., Ge, H.-Z., Wołowicz, A., Wawrzkiewicz, M., Gładysz-Płaska, A., Li, B., Yu, Q.-X., et al. (2021) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2021.112336 · Cited by 192
Luca, M., Di Mauro, M., Di Mauro, M., & Luca, A. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/4730539 · Cited by 190
“, copper, iron, and zinc) accumulated in the neuritic plaques [46], and (4) age-related microglial cell hyperactivation with a subsequent high expression and activation of NADPH oxidase resulting in overproduction of hydrogen peroxide [47].”
BackgroundChen, S., Chang, Y., Li, L., Acosta, D., Li, Y., Guo, Q., Wang, C., Turkes, E., Morrison, C., Julian, D., et al. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01494-6 · Cited by 144
González, J. F., Alcántara, A. R., Doadrio, A. L., & Sánchez-Montero, J. M. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1623201 · Cited by 98
Puentes-Díaz, N., Chaparro, D., Morales-Morales, D., Flores-Gaspar, A., & Alí-Torres, J. (2023) · ACS Omega · doi:10.1021/acsomega.2c06939 · Cited by 67
Metadata
- Authors
- Adlard, P. A., & Bush, A. I.
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2018-03-13
- Volume
- 62
- Issue
- 3
- Pages
- 1369-1379
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2793683106
- Cited by
- 156
- References
- 13
- FWCI
- 13.96
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.